Kala Pharmaceuticals, Inc. (KALA)
NASDAQ: KALA · IEX Real-Time Price · USD
6.75
-0.07 (-0.95%)
At close: May 2, 2024, 4:00 PM
6.82
+0.07 (0.96%)
After-hours: May 3, 2024, 6:34 PM EDT
Kala Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
19.74M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 3.89M | -7.35M | -65.37% |
Dec 31, 2021 | 11.24M | 4.88M | 76.67% |
Dec 31, 2020 | 6.36M | 288.00K | 4.74% |
Dec 31, 2019 | 6.07M | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 45.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ATI Physical Therapy | 699.02M |
Aesthetic Medical International Holdings Group | 96.27M |
MEI Pharma | 72.65M |
Accelerate Diagnostics | 12.06M |
T2 Biosystems | 7.19M |
PAVmed | 2.45M |
AIM ImmunoTech | 202.00K |
BioSig Technologies | 18.00K |
KALA News
- 5 weeks ago - KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 months ago - KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 months ago - KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference - GlobeNewsWire
- 9 months ago - KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - KALA BIO to Participate in Upcoming Investor Conferences in August - GlobeNewsWire
- 10 months ago - Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire